Stock Events

Stock Events

Axsome Therapeutics 

$206.25
157
-$2.10-1.01% 17:44 Today

Statistics

Day High
208.51
Day Low
205.49
52W High
260.19
52W Low
112.9
Volume
152,080
Avg. Volume
853,430
Mkt Cap
10.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.54
-1.19
-0.84
-0.49
Expected EPS
-0.488966
Actual EPS
N/A

Financials

-28.69%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
638.5MRevenue
-183.17MNet Income

Analyst Ratings

278.50Average Price Target
The highest estimate is 316.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
92%
Hold
8%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AXSM. It's not an investment recommendation.
NVIDIA
48
NVDA
Amazon
43
AMZN
Apple
38
AAPL
Microsoft
38
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes develops treatments for major depressive disorder and schizophrenia, overlapping with Axsome's CNS focus.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals subsidiary, offers products that compete in the mental health space.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a strong portfolio in psychiatric and neurological conditions, making it a direct competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries has a broad CNS portfolio, including treatments for neurological conditions.
Novartis
NVS
Mkt Cap292.35B
Novartis offers medications for neurological conditions, competing in the same market as Axsome.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a diverse CNS portfolio, including treatments for psychiatric disorders.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a longstanding presence in the CNS and mental health market, competing with Axsome.
Merck
MRK
Mkt Cap366B
Merck & Co. is involved in the development of CNS treatments, making it a competitor.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, with its acquisition of Allergan, has expanded its CNS portfolio, directly competing with Axsome.

About

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Show more...
CEO
Herriot Tabuteau
Employees
925
Country
United States
ISIN
US05464T1043
WKN
000A2AA7B

Listings

MI
IT
1AXSM.MI
XETRA
DE
19X.XETRA
STU
DE
19X.STU
MX
MX
AZSM.MX

0 Comments

Share your thoughts

FAQ

What is Axsome Therapeutics stock price today?▼
The current price of AXSM is $206.25 USD — it has decreased by -1.01% in the past 24 hours. Watch Axsome Therapeutics stock price performance more closely on the chart.
What is Axsome Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Axsome Therapeutics stocks are traded under the ticker AXSM.
Is Axsome Therapeutics stock price growing?▼
AXSM stock has risen by +3.64% compared to the previous week, the month change is a -2.79% fall, over the last year Axsome Therapeutics has showed a +65.79% increase.
What is Axsome Therapeutics market cap?▼
Today Axsome Therapeutics has the market capitalization of 10.8B
When is the next Axsome Therapeutics earnings date?▼
Axsome Therapeutics is going to release the next earnings report on November 09, 2026.
What were Axsome Therapeutics earnings last quarter?▼
AXSM earnings for the last quarter are -0.99 USD per share, whereas the estimation was -0.89 USD resulting in a -10.98% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Axsome Therapeutics revenue for the last year?▼
Axsome Therapeutics revenue for the last year amounts to 638.5M USD.
What is Axsome Therapeutics net income for the last year?▼
AXSM net income for the last year is -183.17M USD.
How many employees does Axsome Therapeutics have?▼
As of September 04, 2026, the company has 925 employees.
In which sector is Axsome Therapeutics located?▼
Axsome Therapeutics operates in the Health & Wellness sector.
When did Axsome Therapeutics complete a stock split?▼
Axsome Therapeutics has not had any recent stock splits.
Where is Axsome Therapeutics headquartered?▼
Axsome Therapeutics is headquartered in NEW YORK, United States.